Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Clinical Trial of Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

NCT04742400 is registered in ClinicalTrials.gov with National Institute of Neurological Disorders and Stroke (NINDS) as lead sponsor.

NCT NCT04742400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04742400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Clinical Trial of Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Phase
Phase 2
Overall status
Unknown status
Start date
April 15, 2021
Completion date
December 31, 2025
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis